蛋白质组技术鉴定肿瘤相关抗原的研究进展

Advances on identification of tumor associated antigen using proteomics

随着人类基因组测序的完成和蛋白质组技术的发展,采用蛋白质组技术筛选肿瘤相关抗原是近来发展的一种有效、简单的筛选肿瘤抗原的方法。基于蛋白质组技术肿瘤相关抗原的鉴定主要包括两步:一是利用血清学蛋白质组技术筛选自身抗原,二是鉴定目的分子。在多种肿瘤中已经采用该方法鉴定了一些肿瘤抗原,并在肿瘤的诊断、治疗以及预后发挥重要作用。本文主要介绍了基于蛋白质组技术鉴定的肿瘤相关抗原和鉴定抗原的表达情况以及与疾病关系的分析。

In the post-genomic era,the identification of tumor-associated antigens that elicit a humoral response is allowed at the protein level using proteomics.Indeed,the screening of autoantibodies using2-D Western blot experiments with sera fromcancer patients,followed by the subsequent identification of the target protein by mass spectrometry and database search has permitted the exploitation of the B-cell repertoire of patients with cancer.Applied to several types of cancer,a proteomic-based approach has revealed a high frequency of autoantibodies in sera from patients.Several of the antigenic proteins identified may constitute novel cancer markers and may have clinical utility in diagnosis or in establishing prognosis.This reviewis focused on advances on the tumor antigens identified by proteomics.